Ticker >

Eiko Lifesciences share price

Eiko Lifesciences Ltd.

BSE: 540204 SECTOR: Chemicals  6892   5   0

57.80
+0.59 (1.03%)
BSE: 19 Apr 04:01 PM

Price Summary

Today's High

₹ 57.8

Today's Low

₹ 53.35

52 Week High

₹ 81.32

52 Week Low

₹ 46.79

FinStar

Ownership Below Par
Stock price may face volatility due to ownership structure.
ValuationFair
The stock’s market price justifies its intrinsic value.
EfficiencyPoor
The company seems highly inefficient in case of asset management.
FinancialsVery Stable
The company possesses stable growth history and manageable debt.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

80.11 Cr.

Enterprise Value

79.55 Cr.

No. of Shares

1.39 Cr.

P/E

111.26

P/B

1.94

Face Value

₹ 10

Div. Yield

0 %

Book Value (TTM)

₹  29.74

CASH

0.61 Cr.

DEBT

0.05 Cr.

Promoter Holding

24.23 %

EPS (TTM)

₹  0.52

Sales Growth

-27.9%

ROE

2.65 %

ROCE

3.77%

Profit Growth

8.94 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year-27.9%
3 Year∞%
5 Year106.08%

Profit Growth

1 Year8.94%
3 Year81.87%
5 Year33.29%

ROE%

1 Year2.65%
3 Year5.74%
5 Year4.18%

ROCE %

1 Year3.77%
3 Year6.3%
5 Year4.92%

Debt/Equity

0.0018

Price to Cash Flow

18.97

Interest Cover Ratio

7.56557901471529

CFO/PAT (5 Yr. Avg.)

0

Share Holding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Dec 2023 24.23 0
Sep 2023 24.23 0
Jun 2023 23.73 0
Mar 2023 23.73 0
Dec 2022 23.03 0
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has significantly decreased its debt by 4.5741 Cr.
  • Company is virtually debt free.
  • Company has a healthy liquidity position with current ratio of 7.75940602319179.

 Limitations

  • Company has a poor ROE of 5.74400079856365% over the past 3 years.
  • The company is trading at a high PE of 111.26.
  • The company is trading at a high EV/EBITDA of 43.3212.

Quarterly Result (All Figures in Cr.)

PARTICULARS Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023
Net Sales 4.38 6.59 6.51 6.41 6.61
Total Expenditure 4.05 6.23 6.23 6.06 6.15
Operating Profit 0.33 0.36 0.28 0.36 0.46
Other Income 0.19 0.21 0.03 0.03 0.01
Interest 0.01 0.04 0.03 0.06 0.03
Depreciation 0.16 0.16 0.16 0.16 0.16
Exceptional Items 0 0 0 0 0
Profit Before Tax 0.34 0.38 0.11 0.16 0.29
Tax 0.09 0.1 0.03 0.04 0.05
Profit After Tax 0.26 0.28 0.08 0.12 0.24
Adjusted EPS (Rs) 0.27 0.29 0.08 0.12 0.24

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Net Sales 0.36 0 11.99 25.41 18.32
Total Expenditure 0.19 0.17 11.47 24.1 17.36
Operating Profit 0.17 -0.17 0.52 1.31 0.96
Other Income 0.02 0.43 0.46 0.67 0.85
Interest 0.03 0.07 0.09 0.48 0.16
Depreciation 0.06 0.06 0.06 0.56 0.63
Exceptional Items 0 0 0 0 0
Profit Before Tax 0.1 0.13 0.83 0.94 1.03
Tax 0.03 0 0.22 0.24 0.26
Net Profit 0.07 0.13 0.61 0.71 0.77
Adjusted EPS (Rs.) 0.16 0.29 1.39 0.74 0.8

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Equity and Liabilities
Share Capital 3.82 3.82 3.82 8.32 8.32
Total Reserves 1.61 1.66 8.71 20.31 21.11
Borrowings 0.26 0.2 0.13 0.05 0
Other N/C liabilities -0.01 -0.05 -0.02 0.2 0.42
Current liabilities 0.08 0.08 3.96 6.01 1.2
Total Liabilities 5.76 5.71 16.59 34.89 31.04
Assets
Net Block 0.37 0.31 0.25 14.29 13.88
Capital WIP 0 0 0 0 0
Intangible WIP 0 0 0 0 0
Investments 2.13 0.5 0.22 0.2 0.05
Loans & Advances 1.18 3.35 3.61 2.3 6.68
Other N/C Assets 1.37 1.45 1.81 5.67 1.12
Current Assets 0.71 0.1 10.7 12.44 9.3
Total Assets 5.76 5.71 16.59 34.89 31.04
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Profit from operations 0.1 0.13 0.83 0.94 1.03
Adjustment 0.07 0.06 -0.21 0.38 0.02
Changes in Assets & Liabilities -0.33 0.6 -1.27 -8.84 3.1
Tax Paid -0.03 -0.01 -0.18 -0.21 0.08
Operating Cash Flow -0.19 0.77 -0.83 -7.73 4.22
Investing Cash Flow -0.43 -0.65 -2.94 0.59 0.87
Financing Cash Flow -0.08 -0.13 7.81 3.28 -4.7
Net Cash Flow -0.71 -0.01 4.05 -3.85 0.4

Corporate Actions

Investors Details

PARTICULARS Dec 2022% Mar 2023% Jun 2023% Sep 2023% Dec 2023%
promoters 23.03 23.73 23.73 24.23 24.23
bhavesh dhirajlal tanna 2.67 2.67 2.67 2.81 2.81
laxmikant kabra (huf) 9.02 10.08 10.08 10.08 10.08
laxmikant ramprasad kabra... 0.84 0.84 0.84 0.84 0.84
lenus finvest private lim... 10.02 10.14 10.14 10.14 10.14
siddhant laxmikant kabra - - - 0.36 0.36
gaurav ranjitsinh chavda 0.24 - - - -
murlidhar mohanlal lakhia... 0.24 - - - -
PARTICULARS Dec 2022% Mar 2023% Jun 2023% Sep 2023% Dec 2023%
investors 76.97 76.27 76.27 75.77 75.77
2b black bio llp 12.31 12.31 - 13.57 14.60
aritro ashish roy 10.82 10.82 10.82 8.07 6.43
ashika global finance pvt... - - - - 3.49
ashok vishwanath hiremath... 6.01 6.01 6.01 8.90 8.90
deepak jugalkishore chokh... - - - - 1.02
kaushik daga 1.93 1.93 1.93 2.30 2.30
parshva kumar daga 1.43 1.43 1.43 1.71 1.71
sushila paraskumar daga 1.44 1.44 1.44 1.72 1.72
ashika global finance pri... - - 1.53 3.31 -
2b black bio llp . - - 12.31 - -
saima jaid kojar 1.20 1.20 1.20 - -
umesh ravindranath more 6.01 6.01 6.01 - -
vaibhaviben nitinkumar ak... 1.20 1.20 1.20 - -
somisetty malathi latha 1.20 1.08 - - -
kannan ramakrishnan theva... 1.72 - - - -

Annual Reports

Ratings & Research Reports

No Credit and Research reports exist for this company.Report us

Company Presentations

  • PresentationQ4FY21 21 Apr 2021
  • PresentationQ3FY21 11 Feb 2021
  • PresentationQ1FY22 4 Aug 2021

Company News

Eiko LifeSciences acquires 25.01% stake in Reflux Pharmaceuticals19 Apr 2024, 2:29PM Eiko Lifesciences - Quaterly Results8 Feb 2024, 6:05PM Eiko Lifesciences - Quaterly Results8 Feb 2024, 6:05PM Eiko Lifesciences informs about outcome of board meeting 25 Jan 2024, 4:11PM Eiko Lifesciences informs about updates25 Jan 2024, 2:48PM Eiko Lifesciences informs about newspaper publication2 Jan 2024, 6:02PM Eiko Lifescience informs about newspaper advertisement15 Dec 2023, 3:25PM Eiko Lifesciences informs about disclosure 27 Oct 2023, 11:18AM Eiko Lifesciences informs about disclosure11 Aug 2023, 2:23PM Eiko Lifesciences informs about disclosure 3 Aug 2023, 10:06AM Eiko Lifesciences informs about disclosure22 Jul 2023, 11:17AM Eiko Lifesciences informs about disclosure 21 Jul 2023, 2:36PM Eiko Lifesciences informs about disclosure 18 Jul 2023, 10:42AM Eiko Lifesciences - Quaterly Results11 Jul 2023, 6:06PM Eiko Lifesciences - Quaterly Results11 Jul 2023, 6:06PM Eiko Lifesciences - Quaterly Results11 Jul 2023, 6:06PM Eiko Lifesciences inks pact to acquire 25.01% stake in Reflux Pharmaceuticals18 May 2023, 4:14PM Eiko Lifesciences informs about closure of trading window 12 May 2023, 4:05PM Eiko Lifesciences - Quaterly Results9 May 2023, 5:30PM Eiko Lifesciences - Quaterly Results9 May 2023, 5:30PM Eiko Lifesciences - Quaterly Results9 May 2023, 5:30PM Eiko LifeSciences enters into MoU with Vivacious Pharmatex17 Mar 2023, 4:09PM Eiko Lifesciences informs about disclosures 6 Mar 2023, 3:59PM Eiko Lifesciences informs about postal ballot notice1 Feb 2023, 4:46PM Eiko Lifesciences - Quaterly Results17 Jan 2023, 4:43PM Eiko Lifesciences - Quaterly Results17 Jan 2023, 4:43PM Eiko Lifesciences - Quaterly Results17 Jan 2023, 4:43PM Eiko Lifesciences informs about updates30 Dec 2022, 2:49PM Eiko Lifesciences informs about disclosure20 Dec 2022, 11:11AM Eiko Lifesciences informs about disclosure17 Dec 2022, 12:18PM Eiko Lifesciences informs about disclosure 16 Dec 2022, 10:39AM Eiko Lifesciences informs about disclosure 15 Dec 2022, 11:36AM Eiko Lifesciences informs about disclosure 14 Dec 2022, 11:30AM Eiko Lifesciences informs about disclosure 13 Dec 2022, 10:29AM Eiko Lifesciences informs about disclosure 8 Dec 2022, 11:47AM Eiko Lifesciences informs about disclosure7 Dec 2022, 11:15AM Eiko Lifesciences - Quaterly Results21 Oct 2022, 5:10PM Eiko Lifesciences - Quaterly Results21 Oct 2022, 5:10PM Eiko Lifesciences informs about board meeting intimation 14 Oct 2022, 5:12PM Eiko Lifesciences enters into MoU with Delicare Lifesciences29 Aug 2022, 3:58PM Eiko Lifesciences informs about disclosure9 Jun 2022, 12:43PM Eiko Lifesciences informs about disclosure8 Jun 2022, 9:33AM Eiko Lifesciences informs about disclosure3 Jun 2022, 12:00PM Eiko Lifesciences informs about disclosure18 May 2022, 9:45AM Eiko Lifesciences informs about revised disclosures 17 May 2022, 1:21PM Eiko Lifesciences informs about disclosure17 May 2022, 11:00AM Eiko Lifesciences informs about disclosure16 May 2022, 10:20AM Eiko Lifesciences - Quaterly Results22 Apr 2022, 5:01PM Eiko Lifesciences - Quaterly Results22 Apr 2022, 5:01PM Eiko Lifesciences - Quaterly Results22 Apr 2022, 5:01PM

Eiko Lifesciences Stock Price Analysis and Quick Research Report. Is Eiko Lifesciences an attractive stock to invest in?

 

Stock investing requires careful analysis of financial data to find out the company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement. This can be time-consuming and cumbersome. An easier way to find out about a company's performance is to look at its financial ratios, which can help to make sense of the overwhelming amount of information that can be found in a company's financial statements.

Here are the few indispensable tools that should be a part of every investor’s research process.

  • PE ratio: - Price to Earnings' ratio, which indicates for every rupee of earnings how much an investor is willing to pay for a share. A general rule of thumb is that shares trading at a LOW P/E are undervalued (it depends on other factors too). Eiko Lifesciences has a PE ratio of 111.260827718961 which is high and comparatively overvalued .

  • Share Price: - The current share price of Eiko Lifesciences is Rs 57.8. One can use valuation calculators of ticker to know if Eiko Lifesciences share price is undervalued or overvalued.

  • Return on Assets (ROA): - Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. Eiko Lifesciences has ROA of 2.331937042553 % which is a bad sign for future performance. (higher values are always desirable)

  • Current ratio: - The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. Eiko Lifesciences has a Current ratio of 7.75940602319179 .

  • Return on equity: - ROE measures the ability of a firm to generate profits from its shareholders investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. Eiko Lifesciences has a ROE of 2.64866894738837 % .(higher is better)

  • Debt to equity ratio: - It is a good metric to check out the capital structure along with its performance. Eiko Lifesciences has a D/E ratio of 0.0018 which means that the company has low proportion of debt in its capital.

  • Inventory turnover ratio: - Inventory Turnover ratio is an activity ratio and is a tool to evaluate the liquidity of a company's inventory. It measures how many times a company has sold and replaced its inventory during a certain period of time. Eiko Lifesciences has an Inventory turnover ratio of 5.75683021476489 which shows that the management is inefficient in relation to its Inventory and working capital management.

  • Sales growth: - Eiko Lifesciences has reported revenue growth of -27.9022820017393 % which is poor in relation to its growth and performance.

  • Operating Margin: - This will tell you about the operational efficiency of the company. The operating margin of Eiko Lifesciences for the current financial year is 5.2425033021494 %.

  • Dividend Yield: - It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for Eiko Lifesciences is Rs 0 and the yield is 0 %.

Last Updated on:
Brief about Eiko Lifesciences
X